Kiromic BioPharma rises on FDA nod for lung cancer therapy trial
01/05/2023 13:46
** Shares of gene-editing co Kiromic BioPharma Inc KRBP.O
rise 8.26% to $4.39 premarket
** Co says U.S. FDA authorized application to initiate
early-stage clinical trial to evaluate deltacel for patients
with non-small cell lung cancer
** Deltacel is being developed to treat solid tumors in
combination with standard antitumor modality
** Co expects beginning of first in human trial activation
in Q2 2023
** As of last close, stock down ~25% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site